
    
      OUTLINE:

      Patients receive thiotepa intravenously (IV) twice daily (BID) on day -7, treosulfan IV on
      days -6 to -4, fludarabine phosphate IV on days -6 to -2, and rabbit anti-thymocyte globulin
      IV on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via
      infusion on day 0.

      After completion of study treatment, patients are followed up at 1 year and then annually
      thereafter.
    
  